Company starts Phase II study of Alzheimer’s drug – and it’s not going after amyloid beta

Company starts Phase II study of Alzheimer’s drug – and it’s not going after amyloid beta

Tetra Discovery Partners announced the initiation of a Phase II study of BPN14770, which targets phosphodiesterase-4D, or PDE4D. The trial is expected to enroll about 255 patients at 60 sites in the US.

Source: http://bit.ly/2GIcoQs